Loading
Leads the world's first centre dedicated to BRCA-related cancers and the trials of PARP inhibitors plus immunotherapy.
Susan M. Domchek is Executive Director of the Basser Center for BRCA at the Abramson Cancer Center, University of Pennsylvania. She leads the world's first centre dedicated to BRCA-related cancers and is known for trials combining PARP inhibitors with immunotherapy, including MEDIOLA with olaparib plus durvalumab, and for analyses of PARP-inhibitor resistance and reversion in germline BRCA carriers. Her selected paper reports the MEDIOLA study of olaparib and durvalumab in germline BRCA-mutated metastatic breast cancer. Her work spans hereditary breast, ovarian and pancreatic cancer and germline testing.
| Title | Journal | Year |
|---|---|---|
| Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA) | Lancet Oncology | 2020 |
| OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer | New England Journal of Medicine | 2021 |
| PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers | JAMA | 2010 |
Everyone with HER2-negative early breast cancer that meets high-risk criteria should be offered germline BRCA testing, because a positive result now changes treatment: a year of olaparib after chemotherapy reduces relapse and death. It does not apply to low-risk tumours, HER2-positive disease, or somatic-only BRCA mutations.
For women who carry a BRCA mutation, preventive removal of the ovaries and tubes saves lives, and preventive mastectomy almost eliminates breast cancer. These are the strongest prevention effects in oncology, which is why finding carriers before they develop cancer matters so much.
Shares Angelina Jolie, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
Shares PARP, Olaparib, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
Shares PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
Shares PARP, Olaparib, BRCA1 / BRCA2 (HRD), Ovarian cancer.
Shares PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
Shares PARP, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC).
Shares Olaparib, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC).
Shares Angelina Jolie, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.